Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis

Exclusion Criteria

• •Relates to SLE
• •Severe renal impairment as defined by calculated creatinine clearance or MDRD-GFR \< 30 ml/min(except creatinine clearance or MDRD-GFR \> 50 ml/min in the 12 weeks prior to screening)
• •History of serious disease or complication in any organ system that not appropriate to treatment immunosuppressive drug groups.
• •Related to Treatment
• •Previous of any Mycophenolate groups in the 3 months prior to screening.
• •Treatment with more than 2 g Cyclophosphamide in the last 6 months period prior to screening.
• •Receipt of more than 3 g IV pulse methylprednisolone within the last 3 months prior to screening.
• •Receipt of prednisolone dose \> 30 mg/day for longer than 30 days within last 3 months prior to screening.
• •Related to General Health
• •Pregnancy or breast feeding mothers.
• •Evidence of significant uncontrolled concomitant disease in any organ system not related to SLE.
• •History of cancer, including solid tumors, hematological malignancies and carcinoma.
• •History of serious recurrent or chronic infection.
• •Evidence of current abuse of drugs or alcohol.
• •Related to Laboratory Findings
• •Neutrophile \< 1,500/mm3, Hb \< 7g/L, Platelet \< 50,000/mm3 (except active SLE)
• •Positive HBsAg or anti-HCV or anti-HIV.